Manorama Industries surges 14.1% as Q1 PAT jumps 68% on margin expansion
Street latched on to sharp profit growth, margin expansion and a fully funded capex plan in the latest Q1 FY27 investor deck.
Manorama Industries Ltd shares rallied 14.1% in the session after the company published its Q1 FY27 investor presentation, which unpacked a strong quarter and a clearly funded growth roadmap.
The stock reaction appears to be driven by a combination of sharp profit growth, margin expansion, and visibility on capacity-led scaling, rather than any single headline number.
Profit growth and margin expansion stood out
The investor presentation (Q1 FY27 deck dated August 2026) highlights a strong start to FY27 on a consolidated basis:
- Revenue for Q1 FY27: ₹4,040.1 million vs ₹2,895.5 million in Q1 FY26 (39.5% YoY growth).
- EBITDA: ₹1,062.1 million vs ₹747.0 million (42.2% YoY).
- PAT: ₹786.6 million vs ₹469.4 million (67.6% YoY).
- Diluted EPS: ₹13.17 vs ₹7.85, up 67.8% YoY.
(See the consolidated financial table on page 24–25.)
Crucially for the market, profitability improved faster than revenue:
- EBITDA margin rose to 26.3% in Q1 FY27 from 25.8% in Q1 FY26 (an expansion of 49 bps).
- PAT margin climbed to 19.5% from 16.2% (an expansion of 326 bps).
Sequentially, the trend also looked constructive:
- Revenue grew from ₹3,913.4 million in Q4 FY26 to ₹4,040.1 million in Q1 FY27.
- EBITDA increased from ₹974.7 million to ₹1,062.1 million.
- PAT jumped from ₹524.6 million to ₹786.6 million.
- PAT margin improved from 13.4% in Q4 FY26 to 19.5% in Q1 FY27.
The presentation explicitly attributes the margin performance to a “stronger product mix of value-added offerings” and “enhanced operational leverage” (page 24–25). That combination of higher volumes, better mix and improving margins is typically what growth investors look for in a specialty ingredients business.
Integrated model and capacity build-out support the growth story
Beyond the quarter’s numbers, the deck spends considerable space explaining why current profitability may be sustainable.
On page 5, Manorama highlights FY26 consolidated metrics:
- Revenue: ₹13,667 million.
- EBITDA margin: 26.4%.
- PAT margin: 16.5%.
- ROE: 39.4%.
- ROCE: 46.2%.
- Asset turnover: 7.4x.
These figures frame Q1 FY27 not as a one-off spike, but as a continuation of already strong economics.
The capacity and asset-turnover slide on page 13 underscores how operating leverage is being built:
- Fractionation capacity at 47,500 TPA in FY26.
- Standalone FY26 revenue of ₹1,358 crore with 7.4x asset turnover.
- FY22–26 standalone revenue CAGR of 48.5% and fixed asset CAGR of 34.5%.
Investors often reward businesses that can grow revenue faster than the asset base while maintaining or expanding margins, which this deck clearly showcases.
Fully funded capex and global expansion de-risk the growth plan
The presentation also clarifies how the next leg of growth will be financed and executed, which likely helped sentiment.
On page 21–22, Manorama lists key recent developments:
- INR 500 crores QIP raise completed in July 2026 at ₹1,470/share, described as strengthening the balance sheet ahead of the FY28 capex cycle.
- A proposed capex of INR 460 crore over the next 2–3 years (page 13–14), focused on expanding cocoa butter alternatives (CBA), solvent fractionation and refinery capacities in India, and a new refinery of 90,000 TPA within a forward-integration programme (page 13–14).
The “Driving the Next Phase of Growth” slide (page 13–14) sets out clear execution priorities:
- Debottleneck fractionation to 52,000 TPA (expected in FY27).
- Add a 75,000 TPA Fractionation Plant–3 and new CBA/ESOS capacity.
- Set up a processing factory in Burkina Faso to improve efficiency and reduce seed freight.
- Add 300 TPD refining capability.
Because the ₹500 crore QIP exceeds the ₹460 crore proposed capex, the market can see that the bulk of the expansion is already funded through equity, which reduces balance-sheet risk.
Strengthening sourcing and international footprint
The deck also emphasises structural advantages in sourcing and market access, which can justify premium valuations in niche ingredients.
Key points from pages 16–18 and 21–22:
- Presence in 39+ countries with 10 international subsidiaries.
- Export:domestic revenue mix of 60:40 in Q1 FY27.
- Eight sourcing subsidiaries across West Africa, including newly incorporated Manorama Savannah Agro Chad SARL in the Republic of Chad.
- Acquisition of about 10 hectares (24 acres) of land in Burkina Faso for a Shea processing facility, with regulatory clearances pending.
- First commercial production of CBE/specialty fats with Dekel in Brazil and shipment of trial samples to customers.
These steps deepen backward integration in Shea and extend Manorama’s reach into Latin America and MENA, which the company positions as key growth markets for cocoa butter equivalents and specialty fats.
Balance sheet and return metrics add to the appeal
The consolidated balance sheet on page 25–26 shows:
- Total equity of ₹6,821 million as of 31 March 2026 vs ₹4,597 million a year earlier.
- Net debt reduction, reflected in net debt-to-equity falling from 0.83 in FY25 to 0.38 in FY26 (page 26–27).
- Working capital days improving from 150 to 123 (page 26–27).
High returns and improving leverage metrics often underpin re-rating stories. The presentation highlights FY26 consolidated ROE of 39.4% and ROCE of 46.2% (page 26–27), which are elevated for a manufacturing business.
Why the 14.1% move likely ties back to this filing
With no other disclosed market catalysts in the provided context, the 14.1% rise in Manorama Industries’ share price after the investor presentation appears closely linked to how the deck framed the story:
- Strong Q1 FY27 profit growth and margin expansion on a consolidated basis.
- Evidence that higher profitability is supported by capacity, product mix and operating leverage.
- A clearly articulated, largely funded capex plan of ₹460 crore backed by a ₹500 crore QIP.
- Deepening global sourcing and distribution, including new initiatives in Chad, Burkina Faso and Brazil.
The filing does not provide any guidance in terms of explicit revenue or profit targets, nor does it comment on valuations. The size of the stock move therefore likely reflects how investors interpreted this combination of strong current performance and de-risked growth capacity, rather than any single new datapoint.
Track Manorama Industries Ltd
Cruxal reads every Manorama Industries Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
